PROTAC & Targeted Protein Degrader Deal Benchmarks

Median Upfront

$104M

Range: $48M - $159M

Total Deal Value

$1.0B

Range: $558M - $1.5B

Royalty Rate

8.9% - 15.7%

Tiered up to 19.7%

Dev Milestones

$364M

Range: $204M - $525M

Model Your Deal

Market Analysis

Targeted protein degradation has emerged as one of the most actively partnered modalities in oncology, with PROTAC and molecular glue deals commanding significant deal values even at Phase 1. PROTAC deals achieve a median total deal value of $1.0B, with upfront payments ranging from $48M to $159M. The ability to degrade previously undruggable targets drives strong pharma interest.

Due to the early clinical stage, PROTAC deal structures are heavily weighted toward milestones. Development milestones average $364M, reflecting the extensive de-risking required around oral bioavailability, E3 ligase selectivity, and catalytic degradation efficiency. Regulatory milestones of $319M reward progress toward approval.

Royalty rates for PROTAC deals start at 8.9%-15.7% base rates, with escalation reaching 19.7% on peak sales. The 10/90 upfront/milestone split reflects the platform potential to address multiple targets beyond the initial licensed asset.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical total deal value for a PROTAC licensing agreement?

Phase 1 PROTAC deals have a median total deal value of $1.0B, ranging from $558M to $1.5B. Platform deals with multi-target potential can exceed these ranges substantially.

How are PROTAC deal milestones structured?

PROTAC deals allocate approximately 90% of total deal value to milestones. Development milestones ($364M) dominate, followed by commercial milestones ($228M) and regulatory milestones ($319M).

What differentiates high-value PROTAC deals from standard ones?

Premium PROTAC deal terms are driven by target novelty (especially previously undruggable oncology targets), oral bioavailability data, catalytic mechanism of action confirmation, favorable safety profile versus inhibitors, and the breadth of the E3 ligase platform for future programs.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

PROTAC & Targeted Protein Degrader Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule Deals

ADC Deal Benchmarks

Preclinical Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?